Thermatrx sale to fund major initiatives for BSD
This article was originally published in Clinica
Having fattened its wallet with the proceeds from the Thermatrx transaction, BSD Medical is now financially able to "aggressively pursue" the objectives of its corporate strategy. Salt Lake City-based BSD gained $40m from the sale of Thermatrx, a company specifically set up to commercialise BSD's microwave thermal treatment for benign prostate hyperplasia, to American Medical Systems (AMS) in July.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.